Mandal S K, Sagar G, Sahoo M, Jasuja S
Department of Nephrology, Indraprastha Apollo Hospital, New Delhi, India.
Indian J Nephrol. 2012 Mar;22(2):130-2. doi: 10.4103/0971-4065.97134.
Diffuse alveolar hemorrhage is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is a powerful hemostatic agent developed for treatment of bleeding in patients with hemophilia and antibodies to factors VIII or IX. It has been used increasingly in life-threatening hemorrhage in a variety of other settings in which conventional medical or surgical therapy is unsuccessful. We report the successful use of rFVIIa for massive pulmonary hemorrhage in a patient of microscopic polyangiitis, which was later complicated by thrombotic microangiopathy and posterior reversible encephalopathy syndrome.
